Unknown

Dataset Information

0

Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance.


ABSTRACT: Interleukin-10 (IL-10) is a promising candidate for the treatment of inflammatory bowel disease. Intragastric administration of Lactococcus lactis genetically modified to secrete IL-10 in situ in the intestine was shown to be effective in healing and preventing chronic colitis in mice. However, its use in humans is hindered by the sensitivity of L. lactis to freeze-drying and its poor survival in the gastrointestinal tract. We expressed the trehalose synthesizing genes from Escherichia coli under control of the nisin-inducible promoter in L. lactis. Induced cells accumulated intracellular trehalose and retained nearly 100% viability after freeze-drying, together with a markedly prolonged shelf life. Remarkably, cells producing trehalose were resistant to bile, and their viability in human gastric juice was enhanced. None of these effects were seen with exogenously added trehalose. Trehalose accumulation did not interfere with IL-10 secretion or with therapeutic efficacy in murine colitis. The newly acquired properties should enable a larger proportion of the administered bacteria to reach the gastrointestinal tract in a bioactive form, providing a means for more effective mucosal delivery of therapeutics.

SUBMITTER: Termont S 

PROVIDER: S-EPMC1694204 | biostudies-literature | 2006 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance.

Termont Sofie S   Vandenbroucke Klaas K   Iserentant Dirk D   Neirynck Sabine S   Steidler Lothar L   Remaut Erik E   Rottiers Pieter P  

Applied and environmental microbiology 20061006 12


Interleukin-10 (IL-10) is a promising candidate for the treatment of inflammatory bowel disease. Intragastric administration of Lactococcus lactis genetically modified to secrete IL-10 in situ in the intestine was shown to be effective in healing and preventing chronic colitis in mice. However, its use in humans is hindered by the sensitivity of L. lactis to freeze-drying and its poor survival in the gastrointestinal tract. We expressed the trehalose synthesizing genes from Escherichia coli unde  ...[more]

Similar Datasets

| S-EPMC3131666 | biostudies-literature
2018-10-30 | GSE74554 | GEO
| S-EPMC4959180 | biostudies-literature
| S-EPMC2859938 | biostudies-literature
| S-EPMC3255609 | biostudies-literature
| S-EPMC9866448 | biostudies-literature
| S-EPMC7856218 | biostudies-literature
2007-10-04 | GSE9168 | GEO
2009-04-28 | GSE10254 | GEO
| S-EPMC3869327 | biostudies-literature